|
Video: What is a Stock Split?
|
|
Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of product candidates against validated molecular targets in indications of high unmet medical need. AT-007 is a central nervous system penetrant ARI that Co. is developing for the treatment of metabolic diseases, including Galactosemia, a pediatric metabolic disease that affects how the body processes a simple sugar called galactose. AT-001 is an ARI with systemic exposure and peripheral nerve permeability that Co. is developing for the treatment of diabetic cardiomyopathy. AT-003 is an ARI designed to cross through the back of the eye when dosed orally for the treatment of diabetic retinopathy. According to our APLT split history records, Applied Therapeutics has had 0 splits. | |
|
Applied Therapeutics (APLT) has 0 splits in our APLT split history database.
Looking at the APLT split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Applied Therapeutics shares, starting with a $10,000 purchase of APLT, presented on a split-history-adjusted basis factoring in the complete APLT split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
05/15/2019 |
|
End date: |
03/27/2024 |
|
Start price/share: |
$9.75 |
|
End price/share: |
$6.85 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-29.74% |
|
Average Annual Total Return: |
-6.99% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$7,025.88 |
|
Years: |
4.87 |
|
|
|
|
|